1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: generic
Haisco Pharmaceutical Group Co. Ltd. Class A

Haisco Pharmaceutical Group Co. Ltd. Class A

SSZSE:002653
60.45
CNY
+1.46
(+2.47%)
0.80EPS
82.56P/E
74.30BMarket Cap
Oct 28Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.92
1.13
1.14
1.33
1.72
3.19
3.67
3.09
2.57
2.83
3.07
3.29
3.89
4.74
Basic EPS, GAAP
0.48
0.42
0.35
0.41
0.22
0.31
0.46
0.59
0.32
0.26
0.27
0.35
0.23
0.8
Free Cash Flow per Basic Share
0.37
0.25
0.15
0.19
- -
0.11
0.17
-0.37
-0.62
-0.57
0.05
- -
0.4
- -
Dividend per Share
0.28
0.26
0.22
0.27
0.47
0.3
0.22
0.12
0.4
0.23
0.04
0.37
0.3
0.43
Book Value per Share
1.78
1.95
2
2.09
1.84
1.88
2.19
2.7
2.64
2.82
3.75
3.76
3.83
4.3
Tangible Book Value per Share
1.71
1.83
1.72
1.76
1.38
1.3
1.3
1.6
1.24
1.02
1.8
1.64
1.63
2.07
Basic Weighted Avg Shares
1,082
1,073
1,063
1,080
1,080
1,075
1,074
1,079
1,078
1,066
1,093
1,130
1,129
1,117
Sales/Revenue/Turnover
992
1,211
1,212
1,436
1,856
3,427
3,937
3,330
2,773
3,015
3,355
3,721
4,388
5,292
Operating Margin (%)
42.03
32.09
28.08
19.04
12.03
10.03
13.97
13.55
4.26
6.13
12.18
12.34
7.38
18.61
Depreciation Expense
26
43
53
61
63
72
88
105
153
184
220
249
278
- -
Net Income, GAAP
519
451
372
443
238
333
494
637
345
277
295
395
260
898
Effective Tax Rate (%)
8.72
10.7
10.37
9.81
11.47
1.7
13.1
12.8
- -
- -
2.3
- -
5.12
0.06
Profit Margin (%)
52.32
37.22
30.69
30.84
12.8
9.72
12.54
19.12
12.44
9.19
8.8
10.63
5.92
16.96
Working Capital
1,112
1,396
393
1,263
-221
-72
-421
378
30
565
1,137
1,162
1,267
1,206
LT Debt
- -
- -
32
202
- -
255
80
337
463
1,316
866
929
1,011
670
Total Equity
1,927
2,107
2,157
2,245
1,970
1,994
2,377
2,855
2,920
3,133
4,171
4,202
4,288
4,814
Return on Invested Capital (%)
21.36
17.24
13.56
10.08
7.92
10.96
14.54
16.12
- -
- -
5.41
- -
4.06
13.15
Return on Capital (%)
26.68
19.76
14.55
15.93
9.2
12.93
16.72
18.76
- -
- -
5.99
- -
4.69
13.84
Return on Common Equity (%)
28.57
22.34
17.46
20.08
11.21
16.61
22.46
24.14
12.01
9.43
8.18
9.42
6.11
20.1

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
969
1,179
1,594
LT Borrowings
1,002
1,036
650
LT Finance Leases
10
22
20
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,120
1,120
1,120
Market Capitalization
57,474
60,789
74,295

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,834
3,256
3,462
Cash, Cash Equivalents & STI
1,386
1,940
1,980
Accounts Receivable, Net
881
729
872
Inventories
307
328
351
Total Current Liabilities
1,567
1,615
2,256
Payables & Accruals
- -
- -
- -
ST Debt
969
1,179
1,594
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.79%
9.1%
2.04%
Free Cash Flow
2,361.55%
6,477.97%
32,537.68%
Net Income, GAAP
3.07%
-11.87%
-34.36%
Sales/Revenue/Turnover
16.39%
6.42%
17.91%
Total Cash Common Dividend
96.58%
194.3%
-21.06%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
752
935
1,065
970
3,721
2025
892
1,109
- -
1,088
4,388
2026
1,564
1,532
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
0.07
0.19
0.01
0.35
2025
0.04
0.07
- -
-0.03
0.23
2026
0.5
0.26
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.21
0.15
0.01
0.37
2025
0.14
0.14
- -
0.01
0.3
2026
0.01
0.27
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Pang Ke Yan
Full Time Employees
5,597
Sector
Health technology
Industry
Pharmaceuticals: generic
Address
No.17, Sanxiang Avenue Shannan TB China 856000
IPO Date
Jan 6, 2012
Website
haisco.com
Similar Companies
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Teva Pharmaceutical Industries Limited (TASE:TEVA)
Jagsonpal Pharmaceuticals Ltd. (NSE:JAGSNPHARM)
Zim Laboratories Ltd. (NSE:ZIMLAB)
Paradigm Biopharmaceuticals Ltd. (ASX:PAR)
Neuren Pharmaceuticals Limited (ASX:NEU)
Business
Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) researches, develops, manufactures, and sells pharmaceutical products primarily in China, with a focus on innovative chemical drugs and high-end medical instruments; the company operates in key therapeutic areas including anesthesia and analgesia (such as ciclopofol injections), diabetes and complications (such as coglitin tablets), tumors, neuralgia, parenteral nutrition, cardio-cerebrovascular diseases, digestive and respiratory conditions, narcotic analgesics, endocrine system drugs, enteral and parenteral nutrition, neuropsychiatric drugs, cardiovascular drugs, and digestive liver disease treatments. Founded in 2000 and headquartered in Shannan, Tibet Autonomous Region, China, with additional operations in Sichuan, Liaoning, and a U.S. presence via Haisco-USA Pharmaceuticals, Inc., the company maintains a diversified pipeline of over 20 novel chemical entities supported by proprietary platforms in targeted protein degradation, small molecule drug discovery, and inhalation delivery systems. Its self-developed HSK7653 received the second prize in the China (Xiaoshan) Biomedical Industry High-Value Patent Cultivation Competition, and in 2024, its pharmaceutical R&D product line earned the Best Industrial Enterprise award. Recent strategic developments include a 2023 licensing agreement with Chiesi Farmaceutici granting exclusive worldwide rights (ex-China) for HSK31858, a reversible dipeptidyl peptidase 1 inhibitor in Phase 2 for respiratory diseases like bronchiectasis; ongoing Phase II trials for proprietary PDE3/4 inhibitor HSK-39004 in COPD with data expected by year-end 2025, positioning it as a potential out-licensing candidate amid global interest in the target; and leadership recognition in China's parenteral nutrition and liver disease markets.